FDG PET/CT in Breast Cancer Bone Mets

Status Active, not recruiting

Clinical Trial Summary

This study will evaluate baseline uptake on a FDG PET/CT scan in patients with breast cancer that has spread to the bones. A repeat FDG PET/CT scan will be done 4 weeks after the start of new breast cancer hormone treatment and again at 12 weeks after treatment start. The baseline uptake and change in uptake after the repeat scans will be compared to clinical long term outcomes such as time to progression and overall survival. In addition the uptake will be compared to the incidence of skeletal related events that are common occurrences in patients with cancer that has spread to the bones.

Clinical Trial Description

This is an observational study as all patients will receive the same research diagnostic test, an FDG PET/CT study performed at 4 weeks after starting new hormone treatment. ;

Study Design

Related Conditions & MeSH terms

Bone Metastases
Breast Neoplasms
Estrogen Receptor Positive Breast Cancer

Clinical Trial Details

NCT number	NCT01996046
Study type	Observational
Source	University of Pennsylvania
Contact
Status	Active, not recruiting
Phase
Start date	September 2013
Completion date	July 2024

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03986593` - Cryoablation of Bone Metastases From Endocrine Tumors	N/A
Completed	`NCT01358539` - Palliation: the Effect of Education on Pain	Phase 3
Terminated	`NCT00981578` - ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain	N/A
Completed	`NCT00762346` - Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis	Phase 4
Terminated	`NCT00757757` - A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases	Phase 1/Phase 2
Completed	`NCT00420433` - Bone Response in Metastatic Breast Cancer Involving Bones	N/A
Completed	`NCT02826382` - Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041	Early Phase 1
Terminated	`NCT05301062` - A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels
Recruiting	`NCT06367491` - National Database of Bone Metastases
Completed	`NCT03223727` - Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223
Completed	`NCT00830180` - Open Label Extension In Cancer Patients	Phase 2
Active, not recruiting	`NCT03305224` - The Combination Therapy With Ra-223 and Enzalutamide	Phase 2
Withdrawn	`NCT04109937` - External Beam Radiation Therapy Post Surgery in Patients With Lower Extremity Bone Metastases Randomized Efficacy Trial	N/A
Active, not recruiting	`NCT02880943` - Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL)	Phase 1/Phase 2
Completed	`NCT01696760` - Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology	N/A
Completed	`NCT00958477` - A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer	Phase 1
Completed	`NCT03979118` - Exercise Prescription in Patients With Bone Metastases
Completed	`NCT03353090` - Double-bed SPECT/CT for Bone Scintigraphy in Initial Staging of Cancer Patients	N/A
Recruiting	`NCT05167669` - Pain Relief in Symptomatic Bone Metastases With Adjuvant Hyperthermia MR Guided HIFU	Early Phase 1
Recruiting	`NCT04568291` - CTC in Lung Caner Patients With Bone Metastases	N/A